content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Verastem, Inc. (VSTM)

5.41
0.12
(2.27%)
Sep 11, 4:00PM EDT
content_middle

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company’s lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company’s product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Previous Close: 
5.29
Open: 
5.40
Bid: 
5.38
Ask: 
5.49
1yr Target Price: 
10.00
Day's Range: 
5.19 - 5.51
52wk Range: 
1.05 - 5.71
Volume: 
2301442
Average Daily Volume: 
1441650
Market Capitalization: 
200.13M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
36992000M
content_right

Pages